Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8352W HIGH $3.60
Volume
1.30 M
Value Traded
1.37 M
Short % Float
7.34%
Days to Cover
2.1
+10.88%Week
-35.32%1 Month
-53.18%3 Month
-61.04%6 Month
-98.57%5 Year
-98.57%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.76 M
EPS (TTM)
-2.63
P/E Ratio
-
Ent. Value
2.80 M
Total Shares
1.82 M
Float Shares
1.67 M
Insiders
7.84%
Institutions
2.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
XRTX Catalyst Timeline
Dated clinical, regulatory and corporate events for XORTX Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for XORTX Therapeutics Inc.
320Total events
5Upcoming
45Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Partnership / LicenseCorporate
Termination of investor relations agreement with IR Agency LLC
▼Equity OfferingCorporate
Closing of US$5 million public offering of common shares and pre-funded warrants
▼Equity OfferingCorporate
Pricing of US$5 million public offering of common shares and pre-funded warrants
▲AcquisitionVB4-P5Corporate
Acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program closed
kidney diseasesource ↗
◆Partnership / LicenseVB4-P5Corporate
Extension of acquisition closing date for VB4-P5 program from Vectus Biosystems
kidney fibrosissource ↗
▼Reverse Stock SplitCorporate
Share consolidation approved by board, effective March 27, 2026
◆Reverse Stock SplitCorporate
Shareholders approved share consolidation at annual general meeting
●Management ChangeCorporate
Appointment of Krysta Davies Foss to board of directors and grant of options
◆AcquisitionVB4-P5Corporate
Acquisition of Vectus Biosystems' VB4-P5 intellectual property closing deadline
renal anti-fibroticsource ↗
◆Timing GuidanceXORLOPresentation
NDA filing targeted for XRx-026 (XORLO)
allopurinol-intolerant goutsource ↗
●Management ChangeCorporate
Resignation of Bill Farley, Abigail Jenkins and Patrick Treanor from board
▼Equity OfferingCorporate
Closed registered direct offering of common shares and pre-funded warrants for gross proceeds of US$1.1 million
▲Quarterly UpdateCorporate
Received 180-day extension to regain compliance with Nasdaq minimum bid price
▲Partnership / LicenseVB4-P5Corporate
XORTX acquires VB4-P5 program from Vectus Biosystems
kidney fibrosissource ↗
▼Equity OfferingCorporate
Closed non-brokered private placement of 156,849 Units at US$0.73/Unit for gross proceeds of US$114,500
▼Equity OfferingCorporate
Closed non-brokered private placement of units for gross proceeds of US$925,000
▲Patent GrantedIP / Competition
European patent granted for xanthine oxidase inhibitor formulations
gout, hyperuricemia, ADPKD, kidney disease, cardiovascular diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How XRTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every XRTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| XORLOTM Orphan | autosomal dominant polycystic kidney disease (ADPKD) | Phase 3 | 2023-01-19 | substantial increase in the bioavailability of oxypurinol with the XORLOTM formulation platform; increased dose proportionality compared to non-formulated oxypurinol; average increase of exposure of ~40% in oxypurinol compared to the fasted state; increased bioavailability of 100% or more could be achieved with test formulations compared to non-formulated oxypurinol aloneRead More | XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in XRTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in XRTX for Q2 2026. | ||||
Ownership Trends
XRTX Short Interest
Shares sold short, counted twice a month.
7.34%
Short % of Float
of tradable shares sold short
122.5K
Shares Sold Short
-48.3% vs prior count
2.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
58.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XRTX ranks across every disease it competes in
Competitive Position is a premium feature
See how XRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXRTX News
-XRTX
Nov 13, 2026▲ +5.4%today
XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
XORTX Therapeutics announced that the Japan Patent Office has granted a patent for its xanthine oxidase inhibitor compositions aimed at treating acute kidney injury. This patent will support the XRx-101 program and is expected to remain effective until March 2041. The decision enhances XORTX's intellectual property portfolio in Japan, a significant pharmaceutical market.
Read more →-XRTX
Oct 8, 2026▼ -23.8%on this news
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
XORTX Therapeutics plans to submit a Clinical Trial Application for XRx-026 to Health Canada. This application supports a two-part clinical study evaluating XORLO™, a proprietary formulation for gout treatment. The initiative aims to expedite clinical data delivery for a subsequent New Drug Application to the FDA. The company has received inquiries from potential commercialization partners as it advances its regulatory strategy.
Read more →-XRTX
Sep 18, 2026▲ +15.7%on this news
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
XORTX Therapeutics plans to submit an Investigational New Drug application for its XRx-026 gout program to the FDA. The submission is expected in the fourth quarter of 2026, following a two-part clinical trial aimed at characterizing the drug's pharmacokinetics and efficacy. The company estimates a market opportunity exceeding USD $700 million based on previous sales of gout treatments. Successful completion of the trial may lead to a New Drug Application submission within a year.
Read more →-XRTX
Sep 10, 2026▲ +10.4%on this news
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
XORTX Therapeutics has commenced the manufacturing of drug substance and tablets for XORLO™, a treatment for gout. This initiative supports the XRX-OXY-102 clinical study, which follows positive previous trial results. The company is collaborating with a contract manufacturer to ensure the necessary materials for FDA marketing approval. Further updates on regulatory strategies are expected soon.
Read more →-XRTX
Sep 8, 2026▼ -5.4%on this newsshared move
XORTX Re-Engages Investor Relations Program
XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations services following its voluntary delisting from the TSX Venture Exchange. The consulting agreement mirrors previous terms disclosed in earlier news releases. The company is focused on developing treatments for gout and other kidney-related conditions.
Read more →-XRTX
Aug 28, 2026XORTX Announces Termination and Postponement of Investor Relations Program
XORTX Therapeutics has terminated its investor relations agreement with IR Agency LLC and postponed its marketing program as it prepares for a voluntary delisting from the TSX Venture Exchange. The decision aims to reduce regulatory complexity and focus on advancing clinical development. The company plans to re-engage IR Agency LLC post-delisting, expected by September 1, 2026.
Read more →-XRTX
Jul 31, 2026XORTX Announces Director Resignation
XORTX Therapeutics Inc. announced the resignation of Anthony Giovinazzo from its board of directors for personal reasons. Dr. Allen Davidoff, co-CEO, expressed gratitude for Giovinazzo's contributions during his tenure. XORTX is focused on developing therapies for gout and kidney diseases, with several products in various stages of development.
Read more →-XRTX
Jul 29, 2026XORTX Appoints New Director
XORTX Therapeutics has appointed Depesh Narotam as an independent director effective July 27, 2026. Narotam brings over 20 years of experience in financial services, particularly in debt financing and strategic partnerships. His appointment is expected to enhance the board's governance and support the advancement of the company's clinical programs targeting gout and kidney diseases.
Read more →-XRTX
Jun 15, 2026XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
XORTX Therapeutics has announced the appointment of Mika Grasso as Co-CEO and provided a corporate update focusing on its lead program for gout, XRx-026. The company aims to restructure its corporate status and re-initiate drug development programs, with a clear regulatory pathway for submitting a new drug application. Increased investor interest has allowed for expanded activities in drug development, particularly targeting the gout market.
Read more →-XRTX
Jun 12, 2026XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
XORTX Therapeutics has announced its decision to voluntarily delist from the TSX Venture Exchange to reduce costs and streamline operations. The company believes this move will enhance focus on its lead program for gout treatment, XRx-026. Shareholders will still have access to their shares on Nasdaq, and no action is required from them.
Read more →-XRTX
May 19, 2026▼ -10.8%on this news
XORTX Announces Closing of US$5 Million Public Offering
XORTX Therapeutics has successfully closed a public offering, raising $5 million by issuing 2,659,574 common shares and pre-funded warrants. The funds will support working capital and corporate activities, including investor relations. The offering is subject to final approval from the TSX Venture Exchange. XORTX is focused on developing therapies for gout and kidney diseases.
Read more →-XRTX
May 14, 2026▼ -14.1%on this newsshared move
XORTX Announces US$5 Million Public Offering
XORTX Therapeutics Inc. has announced a public offering of 2,659,574 common shares priced at $1.88 each, aiming to raise $5 million. The offering is expected to close on or about May 15, 2026, pending regulatory approvals. XORTX is focused on developing therapies for gout and progressive kidney disease, with several products in various stages of development.
Read more →-XRTX
Apr 21, 2026▲ +19.6%on this news· ran to +35% by day 3
XORTX Meets Nasdaq Continued Listing Requirements
XORTX Therapeutics Inc. has received a compliance letter from Nasdaq after meeting the minimum bid price requirement of $1.00 per share. This was achieved following a 1 for 5 reverse stock split implemented on April 6, 2026. The company is focused on developing therapies for gout and progressive kidney disease, with several products in various stages of development.
Read more →-XRTX
Apr 14, 2026XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
XORTX Therapeutics has finalized the acquisition of the Vectus kidney anti-fibrotic asset, VB4-P5, which targets chronic kidney disease. The program is at the pre-IND stage and addresses a significant unmet medical need. The acquisition includes intellectual property and data from Vectus, enhancing XORTX's development pipeline.
Read more →-XRTX
Apr 1, 2026XORTX Confirms Effective Date of Share Consolidation
XORTX Therapeutics Inc. has confirmed the effective date for its share consolidation, which will occur on April 6, 2026. This consolidation will be on the basis of one new common share for every five old common shares. The company has received all required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. XORTX is focused on developing therapies for gout and progressive kidney disease.
Read more →-XRTX
Mar 26, 2026▼ -9.7%on this news
XORTX Announces Change of Effective Date of Share Consolidation
XORTX Therapeutics has announced a delay in the effective date of its share consolidation from March 27, 2026, to April 6, 2026. This decision is subject to the necessary approvals from the TSX Venture Exchange and Nasdaq. The company focuses on developing therapies for gout and progressive kidney disease, with several products in various stages of development.
Read more →-XRTX
Mar 26, 2026▼ -9.7%on this news
XORTX Announces Results of Annual and Special Meeting of Shareholders
XORTX Therapeutics Inc. announced the results of its annual and special meeting held on March 24, 2026. Approximately 35% of shares were represented, leading to the approval of all proposed matters, including the election of five management nominees and the appointment of auditors. The company continues to focus on developing therapies for gout and kidney diseases.
Read more →-XRTX
Mar 25, 2026XORTX Announces Share Consolidation
XORTX Therapeutics Inc. has announced a share consolidation of one post-consolidation share for every five pre-consolidation shares, effective March 27, 2026. This decision, approved by the TSX Venture Exchange, aims to ensure compliance with NASDAQ's listing requirements. The total number of outstanding shares will decrease significantly, and shareholders will receive instructions for exchanging their shares following the effective date.
Read more →-XRTX
Mar 24, 2026XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
XORTX Therapeutics Inc. announced that shareholders approved a share consolidation at the annual meeting held on March 24, 2026. The consolidation aims to maintain compliance with NASDAQ listing requirements, specifically ensuring shares trade above $1.00. The company currently has 6,962,218 common shares outstanding and plans to consolidate them at a ratio of five to one. The exact number of shares post-consolidation will depend on the rounding of fractional shares.
Read more →-XRTX
Mar 18, 2026▲ +6.4%on this news
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
XORTX Therapeutics Inc. has proposed three new director nominees for its upcoming annual and special meeting of shareholders scheduled on March 24, 2026. This change arises as part of the company's negotiations for a significant financing initiative. However, this move is conditional; if the financing does not proceed, the new nominees will resign from their positions. The company is encouraging shareholders to vote in favor of the resolutions at the meeting.
Read more →About XORTX Therapeutics Inc.
BIOPHARMAWATCH ELITE
Trade the next XRTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime